IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

QUIBELL, Martin et al.

Conf.: 8544

Appl. No.:

10/015,186

Group:

1614

Filed:

November 16, 2001

Examiner: UNASSIGNED

For:

CYSTEIN PROTEASE INHIBITORS

## LETTER

Assistant Commissioner for Patents Washington, DC 20231

August 5, 2002

Sir:

Under the provisions of 35 U.S.C.  $\S$  119 and 37 C.F.R.  $\S$ 1.55(a), the applicant(s) hereby claim(s) the right of priority based on the following application(s):

Country	Application No.	Filed
UNITED KINGDOM	9911417.5	May 18, 1999
PCT/GB	00/01894	May 18, 2000

A certified copy of the above-noted application(s) is(are) attached hereto.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; I hereby ceparticula miresperiters sonnof time fees.

deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope to: Commissioner of Patents and Trademarks, Washington

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

D.C. 20231 on:

BIRCH, STEWART, KOLASCH & BIRCH, LLP

P.O. Box 747

Falls Church, VA 22040-0747

(703) 205-8000

Attachment.







The Patent Office Concept House Cardiff Road Newport South Wales NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the international application filed on 18 MAY 2000 under the Patent Cooperation Treaty at the UK Receiving Office. The application was allocated the number PCT/GB00/01894.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or the inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, L.C. or PLC.

registration under the Companies Act does not constitute a new legal entity but merely jects the company to certain additional company law rules.



Date:

14 December 2001



## REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only
, , , , , , , , , , , , , , , , , , ,
International Application 76 GB 0 0 / 0 1 8 9 4
18 - 05 - 00 International Filing Date , 18 MAY 2000
United Kingdom Patent Office PCT International Application

1 ''	desired) (12 characters	. 406557 MD	
Box No. I TITLE OF INVENTION			
Furanone Derivatives as Inhibitors of Cather	psin S		
Box No. II APPLICANT			
Name and address: (Family name followed by given name; for a legal designation. The address must include postal code and name of country, address indicated in this Box is the applicant's State (that is, country) of refresidence is indicated below.)	entity, full official The country of the esidence if no State	This person is also inventor.	
Mimetrix Limited,		Telephone No.	
Peterhouse Technology Park,		Facsimile No.	
100, Fulbourn Road,		raesimine 140.	
Cambridge CB1 9PT,	•		
United Kingdom.		Teleprinter No.	
State (that is, country) of nationality:	ate (that is, country) o	of residence:	
United Kingdom	United Kins	edom	
This person is applicant for the purposes of:  all designated States	es except the	United States America only  the States indicated in the Supplemental Box	
Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER)	INVENTOR(S)		
Name and address: (Family name followed by given name; for a legal edsignation. The address must include postal code and name of country. I address indicated in this Box is the applicant's State (that is, country) of resof residence is indicated below.)  Peptimmune Inc., 64, Sidney Street, Cambridge, MA 02139, U.S.A.	sidence ij no State	This person is:    X   applicant only     applicant and inventor     inventor only (If this check-box is marked, do not fill in below.)	
State (that is, country) of nationality: U.S.A.  U.S.A.  U.S.A.			
This person is applicant all designated for the purposes of:  all designated	s except the America of A	United States the States indicated in America only the Supplemental Box	
X Further applicants and/or (further) inventors are indicated on a continuation sheet.			
Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE			
The person identified below is hereby/has been appointed to act on beha of the applicant(s) before the competent International Authorities as:	If X ago	ent common representative	
Name and address: (Family name followed by given name; for a legal edesignation. The address must include postal code and	entity, full official name of country.)	Telephone No.	
DAVIES, Jonathan Mark,		+ 44 1223 360350	
Reddie & Grose,		Facsimile No.	
16, Theobalds Road,		+ 44 1223 360280	
London WCLX 8PL,			
United Kingdom.		Teleprinter No.	
<u> </u>		25445 Reddie G	
Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.			